Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Chimerix stock
Learn how to easily invest in Chimerix stock.
Chimerix is a biotechnology business based in the US. Chimerix shares (CMRX) are listed on the NASDAQ and all prices are listed in US Dollars. Chimerix employs 87 staff and has a trailing 12-month revenue of around $33.1 million.
How to buy Chimerix stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – CMRX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Easy to use platform with low fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Chimerix stock price (NASDAQ: CMRX)Use our graph to track the performance of CMRX stocks over time.
Chimerix shares at a glance
|Latest market close||$1.82|
|52-week range||$1.27 - $6.43|
|50-day moving average||$1.98|
|200-day moving average||$2.29|
|Wall St. target price||$7.50|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$1.71|
Buy Chimerix stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Chimerix stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Chimerix price performance over time
|1 week (2023-01-31)||2.82%|
|1 month (2023-01-06)||-2.67%|
|3 months (2022-11-07)||-6.19%|
|6 months (2022-08-05)||-32.09%|
|1 year (2022-02-03)||N/A|
|2 years (2021-02-05)||-81.31%|
|3 years (2020-02-07)||7.69%|
|5 years (2018-02-07)||4.93|
Is Chimerix stock undervalued or overvalued?
Valuing Chimerix stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Chimerix's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Chimerix's P/E ratio
Chimerix's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Chimerix shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||$33.1 million|
|Gross profit TTM||$-71,838,000|
|Return on assets TTM||-22.26%|
|Return on equity TTM||81.17%|
|Market capitalisation||$160.2 million|
TTM: trailing 12 months
Chimerix share dividends
We're not expecting Chimerix to pay a dividend over the next 12 months.
Chimerix share price volatility
Over the last 12 months, Chimerix's shares have ranged in value from as little as $1.27 up to $6.43. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chimerix's is 1.1821. This would suggest that Chimerix's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Chimerix, Inc. , a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc.
Chimerix in the news
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
16 Stocks with the Lowest PE Ratio
Frequently asked questionsWhat percentage of Chimerix is owned by insiders or institutions?
Currently 9.982% of Chimerix shares are held by insiders and 63.097% by institutions. How many people work for Chimerix?
Latest data suggests 87 work at Chimerix. When does the fiscal year end for Chimerix?
Chimerix's fiscal year ends in December. Where is Chimerix based?
Chimerix's address is: 2505 Meridian Parkway, Durham, NC, United States, 27713 What is Chimerix's ISIN number?
Chimerix's international securities identification number is: US16934W1062 What is Chimerix's CUSIP number?
Chimerix's Committee on Uniform Securities Identification Procedures number is: 16934W106
More guides on Finder
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert